Browsing Tag
Eliquis
9 posts
Why Bristol Myers Squibb is giving away Eliquis to Medicaid and what it signals for U.S. drug pricing next
Bristol Myers Squibb will offer Eliquis free to Medicaid under a U.S. pricing deal. Find out what it means for drug pricing, investors, and patients.
Pfizer Q3 2025 earnings beat forecasts as non-COVID drug sales lift margins and EPS guidance
Find out how Pfizer beat Q3 2025 earnings forecasts and raised full-year EPS guidance as non-COVID drugs and cost savings drove profit growth.
Sotyktu joins Eliquis in Bristol Myers’ direct-to-patient experiment — Is this the future of pharma distribution?
Bristol Myers Squibb adds Sotyktu to its DTC channel with 86% discount, reshaping drug pricing and patient access. See why this matters for pharma.
Can Pfizer’s pipeline offset looming patent cliffs despite a stronger 2025 forecast?
Can Pfizer’s oncology and rare disease pipeline replace billions lost to patent cliffs? Explore how the drugmaker compares with Merck, Bristol Myers, and AstraZeneca.
Pfizer beats Q2 2025 earnings expectations and raises profit forecast, but long-term growth questions persist
Pfizer beats Q2 2025 estimates and raises profit guidance, but patent expirations and pricing pressures keep long-term growth questions on the table.
Pfizer stuns Wall Street with booming Q3 earnings and new guidance boost
Pfizer Inc. delivered a financial jolt in its third quarter of 2024, surpassing Wall Street’s expectations and raising…
Zydus Lifesciences bags FDA final approval for Apixaban Tablets
Zydus Lifesciences has bagged final approval from the US Food and Drug Administration (FDA) for Apixaban Tablets, 2.5mg…
Micro Labs, Mylan secure FDA approval for first generics of Eliquis
Micro Labs and Mylan Pharmaceuticals have secured approval from the US Food and Drug Administration (FDA) for two…
Bristol-Myers Squibb to acquire Celgene in $74bn pharma megadeal
Bristol-Myers Squibb has reached a definitive agreement to acquire Celgene Corporation in a monumental cash-and-stock deal worth approximately…